8-K: Corvus Pharmaceuticals Announces Positive Interim Phase 1 Data for Soquelitinib in Atopic Dermatitis and Secures $12.7 Million Through Warrant Exercise

Corvus Pharmaceuticals reports promising interim results from a Phase 1 trial of soquelitinib for atopic dermatitis, showing significant improvement in patients, and secures $12.7 million through warrant exercises.

Summary

• Corvus Pharmaceuticals has released interim data from its Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis.
• The trial is a randomized, double-blind, placebo-controlled study.
• Cohort 1 included 16 patients, with 12 receiving 100 mg of soquelitinib twice daily and 4 receiving a placebo.
• At 28 days, the soquelitinib group showed a 55.9% mean reduction in EASI scores compared to a 27.0% reduction in the placebo group.
• At 58 days, the soquelitinib group showed a 69.1% mean reduction in EASI scores compared to a 19.1% reduction in the placebo group.
• The study also showed that 9 out of 10 patients in the soquelitinib group achieved EASI 50 at day 58, compared to 1 out of 4 in the placebo group.
• Additionally, 4 out of 10 patients in the soquelitinib group achieved EASI 75 at day 58, while no patients in the placebo group achieved this.
• The company also reported that Samlyn Capital exercised warrants for 3,633,978 shares, resulting in approximately $12.7 million in cash proceeds.
• Initial data from Cohort 2, using a 200mg once daily dose, shows efficacy results consistent with Cohort 1.

Sentiment

Score: 8

Explanation: The document presents very positive interim clinical trial results and a significant cash infusion, suggesting a strong positive outlook for the company. The safety profile is also encouraging.

Positives

• Soquelitinib showed a significant improvement in EASI scores compared to placebo at both 28 and 58 days.
• The drug demonstrated a favorable safety profile with no significant safety issues observed.
• The early exercise of warrants provides a substantial cash infusion of $12.7 million.
• The study suggests a potential link between clinical response and reductions in key inflammatory cytokines.
• The treatment effect of soquelitinib appears to begin early, around eight days, and continues throughout the study.
• Initial data from Cohort 2 is consistent with Cohort 1.

Negatives

• Two patients in the soquelitinib group were not available for follow-up at 58 days.
• One patient in the soquelitinib group experienced Grade 1 nausea, though it did not interfere with treatment.
• One patient in the soquelitinib group developed COVID-19, but recovered without complications.

Risks

• The results are based on interim data from a Phase 1 trial, and further studies are needed to confirm these findings.
• The small sample size of the placebo group may limit the generalizability of the results.
• The company's ability to raise additional capital is a risk factor.
• The company's ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials is a risk factor.
• The unpredictability of the regulatory process is a risk factor.

Future Outlook

The company plans to complete the Phase 1 trial and initiate other trials with soquelitinib for immune diseases. They are also continuing with a Phase 3 trial for peripheral T cell lymphoma.

Management Comments

• Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus, stated that the early results show an attractive potential product profile at the lowest dose studied.
• He also highlighted the consistent signs of efficacy, novel mechanism of action, convenient oral administration, and favorable safety profile.

Industry Context

The announcement is significant as it provides further evidence for the potential of ITK inhibition as a novel mechanism for treating immune diseases, particularly atopic dermatitis, which affects a large population. The results position soquelitinib as a potential competitor to existing treatments, including topical and systemic therapies.

Comparison to Industry Standards

• The EASI score reductions observed in the soquelitinib group are promising compared to typical results seen with existing treatments for atopic dermatitis.
• For example, topical corticosteroids, while commonly used, often do not provide sufficient relief for moderate to severe cases, and systemic therapies can have significant side effects.
• The observed EASI 75 response rate of 40% at day 58 in the soquelitinib group is competitive with some biologic therapies, which are often administered via injection.
• The oral administration of soquelitinib offers a potential advantage over injectable biologics in terms of patient convenience.
• Companies like Sanofi and Regeneron with Dupixent, a biologic injectable, are leaders in the atopic dermatitis space, and soquelitinib would be a competitor if it continues to show positive results in further trials.

Stakeholder Impact

• Shareholders will benefit from the positive clinical trial results and the cash infusion.
• Patients with atopic dermatitis may have a new treatment option if soquelitinib continues to show positive results.
• Employees may benefit from the company's progress and financial stability.

Next Steps

• The company will continue to enroll patients in the Phase 1 trial.
• They will continue to monitor the data from the trial as it progresses.
• The company plans to initiate other trials with soquelitinib for immune diseases.
• The company will continue with the Phase 3 trial for peripheral T cell lymphoma.

Key Dates

Keywords

Soquelitinib, Atopic Dermatitis, Eczema, Clinical Trial, ITK Inhibitor, Immunotherapy, Phase 1, EASI Score, Warrant Exercise, Cytokines